Maria Teresa has been on the Board of Directors of the CRS since 2020, serving as Treasurer elect, Treasurer and now Director at Large, serving as Industry Liaison in 2024-2025. As industry member and part of the IFC (Industry Foresight Council), that works with the CRS Board to better leverage the overall value that Industry can bring to the CRS community. Maria Teresa has always pushed for increasing Industry involvement in the CRS community, exerting energy and passion in making sure the connection between CRS and the Industry keeps growing.
Maria Teresa Peracchia is the Global Head of CMC Strategy & Execution in the Sanofi mRNA Center of Excellence, in charge of the End-to-End CMC strategy for the mRNA vaccine portfolio. Maria Teresa joined Sanofi in 1999. She held several positions of increasing responsibility in formulation development, drug delivery and CMC project management. She served as CMC Project Leader for Dupilumab (Dupixent®) developed in collaboration with Regeneron, where she led the CMC team through successful submission, registration and launch of Dupixent®.
Maria-Teresa holds a Ph.D. in Pharmaceutics from the University of Parma, Italy. During her PhD, supervised by Professor Paolo Colombo, she was a Visiting Scientist (1992-1994) in Professor Robert Langer’s lab at MIT, developing PEGylated polymeric nanoparticles. She was a post-doctoral fellow (1995-1998) with Prof. Patrick Couvreur at the University Paris-Saclay, focusing her work on the design of new PEGylated nanoparticles from polymer chemistry to in vivo biodistribution.
Maria Teresa is part of the Sanofi Gender Balance Network that advocates for women, empowering them in the workplace and promoting a culture of diversity.
